Jacob S. Van Naarden
Executive VP, President of Lilly Oncology & Head of Corporate Business DevelopmentMr. Jacob S. Van Naarden, also known as Jake, is Head of Corporate Business Development, Executive VP & President of Lilly Oncology at Eli Lilly and Company. He was Executive VP & President of Loxo of Eli Lilly and Company. He joined Eli Lilly and Company in 2019. He is the Chief Executive Officer of Loxo Oncology, Inc. He served as Senior Vice President & President of Lilly Oncology at Eli Lilly and Company since September 5, 2021 and serves as its Executive Vice President President of Lilly Oncology since 2021. He serves as Director at Delfi Diagnostics, Inc. since June 2022. He was the Chief Operating Officer of Loxo Oncology, Inc. since January 2, 2019. Mr. Van Naarden was Chief Business Officer at Loxo Oncology, Inc. since December 2015 until December 2018 and served as a Vice President of Corporate Development and Strategy since July 2014. Mr. Van Naarden served as an Analyst at Aisling Capital LLC. Previously, he was an Analyst in the Healthcare Group of Goldman Sachs’s Investment Banking Division, where he worked closely with management of companies across the worldwide healthcare industry, primarily in pharmaceuticals and biotechnology, in the evaluation and execution of acquisitions, financings and corporate strategy. Mr. Van Naarden received an A.B. from Princeton University, awarded Phi Beta Kappa and magna cum laude, in molecular biology.
Positions
- Company NameEli Lilly and CompanyStock CodeLLYPositionExecutive VP, President of Lilly Oncology & Head of Corporate Business DevelopmentColleagues
- DADavid A. RicksChairman, President & CEO
- LELucas E. MontarceExecutive VP & CFO
- DMDaniel M. SkovronskyChief Scientific & Product Officer and President of Lilly Research Laboratories
- AHAnat HakimExecutive VP, General Counsel & Secretary
- STSidney TaurelChairman Emeritus
- RARalph AlvarezIndependent Director
- JRJuan Ricardo LucianoLead Independent Director
- JJJamere JacksonIndependent Director
